ChemoMetec AS (LTS:0DZ0) Owner Earnings per Share (TTM): 9.54 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DZ0 ChemoMetec AS LTS:0DZ0
90 GF Score
Price kr533.00
GF Value kr520.70
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is ChemoMetec AS Owner Earnings per Share (TTM)?

ChemoMetec AS LTS:0DZ0 +2.91% 90 Owner Earnings per Share (TTM) is 9.54 as of Jun. 2026. GuruFocus rates LTS:0DZ0 with a GF Score™ of 90/100 and a GF Value™ of kr520.70 (Fairly Valued). The stock has 3 warning signs investors should review. Among 318 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 74.53% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ChemoMetec AS does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for ChemoMetec AS's Owner Earnings per Share (TTM) or its related term are showing as below:

LTS:0DZ0' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 33.68   Med: 92.81   Max: 274.22
Current: 50.49


During the past 13 years, the highest Price-to-Owner-Earnings ratio of ChemoMetec AS was 274.22. The lowest was 33.68. And the median was 92.81.


LTS:0DZ0's Price-to-Owner-Earnings is ranked worse than
74.53% of 318 companies
in the Medical Devices & Instruments industry
Industry Median: 25.765 vs LTS:0DZ0: 50.49

ChemoMetec AS's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was kr6.20. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was kr11.60. It's PE Ratio (TTM) ratio for today is 45.94.

ChemoMetec AS's EPS without NRI for the six months ended in Jun. 2026 was kr6.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr11.60. It's PE Ratio without NRI ratio for today is 45.94.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by FactSet. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


ChemoMetec AS Owner Earnings per Share (TTM) Related Terms


ChemoMetec AS Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for ChemoMetec AS's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS Owner Earnings per Share (TTM) Chart

ChemoMetec AS Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.06 7.53 6.12 8.10 9.27

ChemoMetec AS Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.81 6.67 7.76 7.82 8.91

LTS:0DZ0 vs ABT, SYK, MDT: Owner Earnings per Share (TTM) Comparison

For the Medical Devices subindustry, ChemoMetec AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoMetec AS Price-to-Owner-Earnings vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ChemoMetec AS's Price-to-Owner-Earnings falls into.


LTS:0DZ0
90GF Score
ChemoMetec AS LTS:0DZ0
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ChemoMetec AS Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

ChemoMetec AS does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.

What does a Owner Earnings per Share (TTM) of 9.54 mean?
ChemoMetec AS (LTS:0DZ0) has a Owner Earnings per Share (TTM) of 9.54 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on ChemoMetec AS. According to the industry distribution chart, ChemoMetec AS ranks #237 out of 318 companies in the Medical Devices & Instruments industry, placing it in the top 74.5%.
Is ChemoMetec AS's Owner Earnings per Share (TTM) too high?
ChemoMetec AS's current Owner Earnings per Share (TTM) is 9.54. The Medical Devices & Instruments industry median Owner Earnings per Share (TTM) is 25.77. ChemoMetec AS's value of 9.54 is 63% below this industry median. Based on the distribution chart, ChemoMetec AS ranks #237 out of 318 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Owner Earnings per Share (TTM) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #237 out of 318 companies for Owner Earnings per Share (TTM). This places ChemoMetec AS in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 25.77. ChemoMetec AS's value of 9.54 is 63% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Medical Devices & Instruments company?
The median Owner Earnings per Share (TTM) among Medical Devices & Instruments companies is 25.77, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current Owner Earnings per Share (TTM) of 9.54 is 63% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on ChemoMetec AS. For the Medical Devices & Instruments industry, the median Owner Earnings per Share (TTM) is 25.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Owner Earnings per Share (TTM) is 9.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (LTS:0DZ0) is currently considered Fairly Valued. The stock's GF Value™ is kr520.70, compared to a current price of kr533.00 — trading 2.4% above its estimated fair value. The current Owner Earnings per Share (TTM) is 9.54 and 63% below the Medical Devices & Instruments industry median of 25.77. ChemoMetec AS's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For ChemoMetec AS (LTS:0DZ0), the current Owner Earnings per Share (TTM) is 9.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ChemoMetec AS (LTS:0DZ0) Overvalued in 2026?

Based on GuruFocus' analysis, ChemoMetec AS stock appears to be overvalued. The current stock price of kr533.00 is trading 2.4% above its estimated GF Value™ of kr520.70. GuruFocus considers ChemoMetec AS to be Fairly Valued.

Key valuation signals for LTS:0DZ0:

  • Owner Earnings per Share (TTM): 9.54
  • GF Value™: kr520.70 vs. price of kr533.00 (2.4% above fair value)
  • GF Score™: 90/100 with 3 warning signs
  • Industry Position: 63% below the Medical Devices & Instruments median (#237 of 318)

No single metric tells the full story. See the LTS:0DZ0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ChemoMetec AS Business Description

Address Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
90GF Score

Get the complete analysis for LTS:0DZ0

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr533.00
Price
kr520.70
GF Value